Cargando…

Oral and vulvo-vaginal lichenoid reactions due to mitotane (Lysodren): A case report

BACKGROUND: The purpose of pharmacovigilance (drug safety) is collection, detection, assessment, monitoring, and prevention of adverse effects with pharmaceutical products. It is meant to identify, characterize, prevent, or minimize actual or potential risks relating to medicinal products. To preven...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmouchkovitch, Arthur, Herry, Héloïse, Thuillier, Philippe, Kerlan, Véronique, Fleuret, Camille, Le Toux, Guy, Boisramé, Sylvie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266149/
https://www.ncbi.nlm.nih.gov/pubmed/28079787
http://dx.doi.org/10.1097/MD.0000000000005075
_version_ 1782500415588270080
author Schmouchkovitch, Arthur
Herry, Héloïse
Thuillier, Philippe
Kerlan, Véronique
Fleuret, Camille
Le Toux, Guy
Boisramé, Sylvie
author_facet Schmouchkovitch, Arthur
Herry, Héloïse
Thuillier, Philippe
Kerlan, Véronique
Fleuret, Camille
Le Toux, Guy
Boisramé, Sylvie
author_sort Schmouchkovitch, Arthur
collection PubMed
description BACKGROUND: The purpose of pharmacovigilance (drug safety) is collection, detection, assessment, monitoring, and prevention of adverse effects with pharmaceutical products. It is meant to identify, characterize, prevent, or minimize actual or potential risks relating to medicinal products. To prevent these adverse effects and improve our practice, health professionals have a duty to report side effects to assess this risk and evaluate the benefit/risk requirements. Mitotane (Lysodren) is used for treating adrenocortical carcinoma. Currently, no side effects concerning oral and genital mucosa have been reported. CASE SUMMARY: This case report is about a 50 years old woman. Six months after the initiation on mitotane treatment, she developed erosive lesions located on the oral and vaginal mucosa. These drug reactions were diagnosed as erosive lichen planus by the biopsy. This lichenoid lesions were resistant to the usual treatments, mitotane being at the time not replaceable. CONCLUSION: This case describes an unreported adverse effect of mitotane, it is – to our knowledge – the 1st description of erosive lichenoid drug reaction due to Mitotane.
format Online
Article
Text
id pubmed-5266149
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-52661492017-02-07 Oral and vulvo-vaginal lichenoid reactions due to mitotane (Lysodren): A case report Schmouchkovitch, Arthur Herry, Héloïse Thuillier, Philippe Kerlan, Véronique Fleuret, Camille Le Toux, Guy Boisramé, Sylvie Medicine (Baltimore) 5900 BACKGROUND: The purpose of pharmacovigilance (drug safety) is collection, detection, assessment, monitoring, and prevention of adverse effects with pharmaceutical products. It is meant to identify, characterize, prevent, or minimize actual or potential risks relating to medicinal products. To prevent these adverse effects and improve our practice, health professionals have a duty to report side effects to assess this risk and evaluate the benefit/risk requirements. Mitotane (Lysodren) is used for treating adrenocortical carcinoma. Currently, no side effects concerning oral and genital mucosa have been reported. CASE SUMMARY: This case report is about a 50 years old woman. Six months after the initiation on mitotane treatment, she developed erosive lesions located on the oral and vaginal mucosa. These drug reactions were diagnosed as erosive lichen planus by the biopsy. This lichenoid lesions were resistant to the usual treatments, mitotane being at the time not replaceable. CONCLUSION: This case describes an unreported adverse effect of mitotane, it is – to our knowledge – the 1st description of erosive lichenoid drug reaction due to Mitotane. Wolters Kluwer Health 2017-01-13 /pmc/articles/PMC5266149/ /pubmed/28079787 http://dx.doi.org/10.1097/MD.0000000000005075 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 5900
Schmouchkovitch, Arthur
Herry, Héloïse
Thuillier, Philippe
Kerlan, Véronique
Fleuret, Camille
Le Toux, Guy
Boisramé, Sylvie
Oral and vulvo-vaginal lichenoid reactions due to mitotane (Lysodren): A case report
title Oral and vulvo-vaginal lichenoid reactions due to mitotane (Lysodren): A case report
title_full Oral and vulvo-vaginal lichenoid reactions due to mitotane (Lysodren): A case report
title_fullStr Oral and vulvo-vaginal lichenoid reactions due to mitotane (Lysodren): A case report
title_full_unstemmed Oral and vulvo-vaginal lichenoid reactions due to mitotane (Lysodren): A case report
title_short Oral and vulvo-vaginal lichenoid reactions due to mitotane (Lysodren): A case report
title_sort oral and vulvo-vaginal lichenoid reactions due to mitotane (lysodren): a case report
topic 5900
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266149/
https://www.ncbi.nlm.nih.gov/pubmed/28079787
http://dx.doi.org/10.1097/MD.0000000000005075
work_keys_str_mv AT schmouchkovitcharthur oralandvulvovaginallichenoidreactionsduetomitotanelysodrenacasereport
AT herryheloise oralandvulvovaginallichenoidreactionsduetomitotanelysodrenacasereport
AT thuillierphilippe oralandvulvovaginallichenoidreactionsduetomitotanelysodrenacasereport
AT kerlanveronique oralandvulvovaginallichenoidreactionsduetomitotanelysodrenacasereport
AT fleuretcamille oralandvulvovaginallichenoidreactionsduetomitotanelysodrenacasereport
AT letouxguy oralandvulvovaginallichenoidreactionsduetomitotanelysodrenacasereport
AT boisramesylvie oralandvulvovaginallichenoidreactionsduetomitotanelysodrenacasereport